Company intelligence / Profile preview

Zomagen Biosciences

London, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

VTX3232, their CNS-penetrant NLRP3 inhibitor, completed a Phase 2a trial in early-stage Parkinson’s disease, showing positive safety and biomarker results, with significant reductions in NLRP3-related biomarkers in CSF and plasma.

Therapeutic areas: NeurologyEndocrinologyCardiovascular
Modalities: Small moleculeSynthetic peptide
Industry: Biotech

Partnerships

Ventyx Biosciences (clinical data sharing for VTX3232)

Beyond the preview

Go deeper on Zomagen Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zomagen Biosciences.

Explore the full profile